Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

PPARGC1A Gene Variants May Be Linked To Some Parkinson’s Types

Patients with early-onset or familial forms of Parkinson’s disease (PD) had a higher burden of rare mutations in the PPARGC1A gene compared with healthy people, whereas no significant relationship was observed between these mutations and late-onset sporadic Parkinson’s, a study found. While the findings suggest that PPARGC1A could contribute to the…

Sleep Problems in Parkinson’s May Be Linked to Certain Medications

Sleep disturbances are common in people with diseases marked by alpha-synuclein buildup, but they are especially problematic among Parkinson’s disease patients on dopaminergic medications, a study suggests. Parkinson’s patients tend to have more arousals during sleep and fewer normal sleep cycles than people with isolated rapid eye movement (REM)…

Exercise Eases Motor Symptoms in Parkinson’s Early-to-mid Stages

At least six months of physical therapy helps to ease motor symptoms, possibly allowing for lower medication doses among people with mild-to-moderate Parkinson’s disease, according to findings from a recent meta-analysis of published clinical trial data. Beneficial changes in Parkinson’s motor symptoms were observed regardless of whether patients…

Researchers Design New Approach to Help Medications Enter the Brain

Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…

Buntanetap Shows Efficacy, Supports Soon-to-open Phase 3 Study

Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…

More, Worse Parkinson’s Pain for Women Than Men, Study Reveals

Women with Parkinson’s disease experience more and worse pain than men with the neurodegenerative condition, according to a new study that highlights sex differences in the prevalence and severity of these symptoms. Chronic pain, pain related to motor symptom fluctuations, mouth/face (oro-facial) pain, and discoloration/swelling were all more prevalent…

Stigma of Parkinson’s Influenced by Other Conditions

More co-existing health conditions in people with Parkinson’s disease is associated with a greater self-perception of stigma and a lower quality of life, a study has found. Thyroid disease, depression and anxiety each were linked to stigma and life quality, with demographic factors — including a younger age, less education…